Tag Archives: SS1P

Finding May Strengthen New Mesothelioma Therapy

NIH scientists believe they may have found a way to help ensure the effectiveness of a new mesothelioma drug called SS1P. SS1P is currently in clinical trials for malignant pleural mesothelioma, a rare but virulent cancer caused by asbestos inhalation. SS1P works by targeting mesothelin, an antigen expressed on the surface of several types of human cancer cells. In mesothelioma cells, mesothelin is frequently ‘shed’ and ends up in the fluid around the lungs, where it is often used to help make a diagnosis. Unfortunately, this ‘shedding’ reduces the effectiveness of SS1P and other therapies that attempt to use mesothelin to find and target mesothelioma cells with anti-cancer drugs. Like the shed mesothelin, the anti-cancer drugs can simply end up … Continue reading Finding May Strengthen New Mesothelioma Therapy »